A Phase III Trial of ALIMTA vs Docetaxel in Patients with Locally Advanced or Metastasic Non-Small Lung Cancer (NSCLC) who were previously treated with Chemotherapy

Grants and Contracts Details

StatusFinished
Effective start/end date12/1/0010/31/04

Funding

  • Eli Lilly and Company: $12,186.00